Plexxikon

Plexxikon, Inc. is engaged in the discovery and development of small molecule drugs for the treatment of human diseases. By accelerating drug discovery through high-throughput crystallography and focusing on genetic mutations that drive disease proliferation, Plexxikon has earned a reputation as a leader in targeted drug discovery and translational personalized medicine. The company also advances drug discovery and early-stage internal drug development. Its product portfolio includes PLX204 for the treatment of diabetes; PLX4032 for melanoma and colorectal cancer; and the kinase inhibitor PLX5568 for pain, polycystic kidney disease, rheumatoid arthritis, and other conditions.